Cited by 53Computational Drug Discovery MethodsHIV/AIDS drug development and treatmentProtein Structure and Dynamics

Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.

Kar, Parimal, Lipowsky, Reinhard, Knecht, Volker·2013·The Journal of Physical Chemistry B

Abstract

Both KNI-10033 and KNI-10075 are high affinity preclinical HIV-1 protease (PR) inhibitors with affinities in the picomolar range. In this work, the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) method has been used to investigate the potency of these two HIV-1 PR inhibitors against the wild-type and mutated proteases assuming that potency correlates with the affinity of the drugs for the target protein. The decomposition of the binding free energy reveals the origin of binding affinities or mutation-induced affinity changes. Our calculations indicate that the mutation I50V causes drug resistance against both inhibitors. On the other hand, we predict that the mutant I84V causes drug resistance against KNI-10075 while KNI-10033 is more potent against the I84V mutant compared to wild-type protease. Drug resistance arises mainly from unfavorable shifts in van der Waals interactions and configurational entropy. The latter indicates that neglecting changes in configurational entropy in the computation of relative binding affinities as often done is not appropriate in general. For the bound complex PR(I50V)-KNI-10075, an increased polar solvation free energy also contributes to the drug resistance. The importance of polar solvation free energies is revealed when interactions governing the binding of KNI-10033 or KNI-10075 to the wild-type protease are compared to the inhibitors darunavir or GRL-06579A. Although the contributions from intermolecular electrostatic and van der Waals interactions as well as the nonpolar component of the solvation free energy are more favorable for PR-KNI-10033 or PR-KNI-10075 compared to PR-DRV or PR-GRL-06579A, both KNI-10033 and KNI-10075 show a similar affinity as darunavir and a lower binding affinity relative to GRL-06579A. This is because of the polar solvation free energy which is less unfavorable for darunavir or GRL-06579A relative to KNI-10033 or KNI-10075. The importance of the polar solvation as revealed here highlights that structural inspection alone is not sufficient for identifying the key contributions to binding affinities and affinity changes for the design of drugs but that solvation effects must be taken into account. A detailed understanding of the molecular forces governing binding and drug resistance might assist in the design of new inhibitors against HIV-1 PR variants that are resistant against current drugs.

Integrity signals

Registry

Crossref · 10.1021/jp3085292

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The desolvation of polar or charged groups of the protein or ligand is unfavorable to binding when the formed solute-solvent interactions are not effectively satisfied upon protein-ligand binding.

    “At the same time, the desolvation of polar or charged groups of the protein or ligand is unfavorable to binding when the formed solute–solvent interactions are not effectively satisfied upon the protein–ligand binding (Blaber et al., 1993; Kar et al., 2013).”
  • The unfavorable desolvation effect from burying polar groups after ligand binding plays an important role in the binding event, but it is commonly neglected by most scoring functions.

    “The unfavorable desolvation effect from burying polar groups after ligand binding also plays an important role in the binding event, but it is commonly neglected by most scoring functions (Kar et al., 2013; Li et al., 2014c; Cramer et al., 2017).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kar, P., Lipowsky, R., & Knecht, V.
Affiliations
Max Planck Institute of Colloids and Interfaces (DE)
Corresponding author
Knecht, Volker
Venue
The Journal of Physical Chemistry B
Published
2013-05-08
Volume
117
Issue
19
Pages
5793-5805
ISSN
  • 1520-5207 (ISSN-L)
  • 1520-6106
OpenAlex
W2083946713
Cited by
53
References
66
Citations by year
2026: 1 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 12 · 2020: 9 · 2019: 6 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 1
FWCI
2.19
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Physical Chemistry B (publishedVersion)
  • PubMed (publishedVersion)
  • Max Planck Institute for Plasma Physics (submittedVersion)
  • Max Planck Digital Library (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
Topics
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
HIV-1 protease inhibitors, configurational entropy, drug resistance, binding free energy decomposition, MM-PBSA, darunavir, antiretroviral drug design
MeSH terms
Mutation, Protein Conformation, Protons, Solvents, Drug Design, HIV Protease, HIV Protease Inhibitors, Entropy, Molecular Dynamics Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review